mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.034 |
0.3 |
mRNA |
I-BET151 |
CTRPv2 |
pan-cancer |
AAC |
0.032 |
0.3 |
mRNA |
TL-2-105 |
GDSC1000 |
pan-cancer |
AAC |
0.034 |
0.3 |
mRNA |
BRD-K99584050 |
CTRPv2 |
pan-cancer |
AAC |
-0.054 |
0.3 |
mRNA |
foretinib |
GDSC1000 |
pan-cancer |
AAC |
0.034 |
0.3 |
mRNA |
Bexarotene |
CTRPv2 |
pan-cancer |
AAC |
-0.036 |
0.3 |
mRNA |
Mitomycin-C |
GDSC1000 |
pan-cancer |
AAC |
0.036 |
0.3 |
mRNA |
ciclosporin |
CTRPv2 |
pan-cancer |
AAC |
-0.037 |
0.3 |
mRNA |
Cytarabine |
CTRPv2 |
pan-cancer |
AAC |
0.028 |
0.3 |
mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.035 |
0.3 |